Las Vegas—Primary acquired melanosis (PAM) of the conjunctiva is an uncommon but important disease. Although some studies have suggested that it occurs in as much as one-third of the population, most cases do not need treatment. The disease is potentially malignant, however, and arguments can be made for early treatment if risk factors are present, said Jerry A. Shields, MD, in his delivery of the Lorenz E. Zimmerman Lecture here at a combined meeting of the American Academy of Ophthalmology and the American Association of Ocular Pathologists.
London—One-year data from an eye-to-eye comparison study of the IntraLase femtosecond laser (IntraLase Corp.) versus the Hansatome mechanical microkeratome (Bausch & Lomb) in myopic LASIK with the VISX Custom-Vue platform (Advanced Medical Optics/VISX) showed that refractive outcomes in both of the groups were excellent and identical despite clinically and statistically significant differences favoring the femtosecond laser earlier in the study.
London—Thin, shallow corneal flaps of approximately 80 to 90 ?m created with an IntraLase femtosecond laser (IntraLase Corp.) may produce the best results in refractive surgery, effectively eliminating pain and haze while producing long-term visual stability, said John Marshall, PhD, in a keynote address during a session on femtosecond lasers here at the XXIV Congress of the European Society of Cataract and Refractive Surgeons (ESCRS).
London—In a comparison of visual outcomes with the femtosecond laser and mechanical microkeratomes following LASIK, both were very effective at targeting emmetropia. Eyes treated with the femtosecond laser, however, had faster visual recovery and better uncorrected visual acuity (UCVA) results at 3 months despite experiencing more transient symptoms immediately after surgery, reported Capt. Steve Schallhorn, MD, here at the XXIV Congress of the European Society of Cataract and Refractive Surgeons.
The problem of tissue drag, which once plagued ophthalmic surgeons, is largely a thing of the past?thanks to groundbreaking work conducted several decades ago by Leonard Apt, MD, currently professor of ophthalmology at the Jules Stein Eye Institute, University of California, Los Angeles (UCLA).
This year's scientific program includes more than 500 peer-reviewed courses.
Editor's Note: Part 1 of this two-part feature (see Ophthalmology Times, Sept. 15, 2006) presented a customer-focused approach for persuading patients to undergo LASIK or a premium cataract procedure. At the heart of this method is training staff to concentrate on identifying patients' needs and how to meet their expectations, rather than jumping to the cost or postsurgical outcomes.
Irvine, CA—Intravitreous dexamethasone in a biodegradable, extended-release implant (Posurdex, Allergan) produced significant improvements in visual acuity and was well tolerated in recent studies. Additional investigation comparing applicator versus incisional placement suggests that the applicator approach is quicker, is at least as safe, and results in similar outcomes, according to Baruch D. Kuppermann, MD, PhD.
Madison, WI—Results from a recent study have shown for the first time the potential of anti-vascular endothelial growth factor (VEGF) therapy to improve features of diabetic retinopathy, according to Micheal M. Altaweel, MD.
About one-third of patients displayed improvement in visual acuity at 1, 2, and 3 months after injection.